金水宝胶囊联合氯沙坦钾干预高血压病阴阳两虚证患者早期肾损害的临床观察  

Jinshuibao Capsule Combined Losartan Potassium Intervened Early Renal Damage of Hypertension Patients of Yin and Yang Deficiency: a Clinical Research

作　　者：张成秋[1] 殷济清[1] 辛青[1] 王雅琴[1] 葛志明[2] 

机构地区：[1]山东大学校医院心内科,济南250061 [2]山东大学齐鲁医院心内科,济南250014

出　　处：《中国中西医结合杂志》2013年第6期731-735,共5页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家自然科学基金资助项目(No.61174218)

摘　　要：目的观察金水宝胶囊联合氯沙坦钾对高血压病阴阳两虚证患者的血清胱抑素C(cystatin C,CysC)、β2-微球蛋白(β2-microglobulin,β2-MG)、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)、尿酸(uric acid,UA)以及血压、血脂、空腹血糖(fasting blood glucose,FBG)水平的影响。探讨其对高血压病早期肾损害的保护作用和对血糖、血脂代谢的影响。方法 106例高血压病阴阳两虚证患者,随机分为对照组(氯沙坦钾组)53例、治疗组(金水宝胶囊联合氯沙坦钾组)53例,经16周治疗后,观察患者血清UA、CysC、β2-MG、hs-CRP、FBG及血脂[包括总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)]水平的变化,评价金水宝胶囊联合氯沙坦钾对肾脏的保护作用和对糖脂代谢的影响。结果与本组治疗前比较,两组患者治疗后收缩压均有所下降,差异有统计学意义(P<0.05,P<0.01),但组间比较差异无统计学意义(P>0.05),两组舒张压下降不明显,差异无统计学意义。与本组治疗前比较,对照组治疗后LDL-C明显下降(P<0.05),FBG、TC、HDL-C、TG各项指标变化不明显,与治疗前比较,差异无统计学意义(P>0.05);治疗组FBG、TC、LDL-C较治疗前均有明显下降,差异有统计学意义(P<0.05,P<0.01),与对照组治疗后比较,差异无统计学意义(P>0.05)。与本组治疗前比较,两组治疗后UA、CysC、β2-MG及hs-CRP均降低,差异有统计学意义(P<0.05,P<0.01),且治疗组SCr较治疗前下降,差异有统计学意义(P<0.05);与对照组同期比较,治疗组治疗后CysC、β2-MG及hs-CRP降低更为显著,差异有统计学意义(P<0.01)。结论金水宝胶囊联合氯沙坦钾中西医结合治疗高血压病阴阳两虚证患者的早期肾损害,效果更明显,更能有效保护和稳定肾功能;金水宝胶囊具有调节血脂和血糖的作用Objective To observe the effects of Jinshuibao Capsule （JC） combined Iosartan po- tassium on some indices of early renal damage of hypertension patients of yin and yang deficiency syn- drome （YYDS）, such as levels of serum cystatin C （Cys C）, β2-microglobulin （β2-MG）, hypersensitive C-reactive protein （hs-CRP）, uric acid （UA）, blood pressure, blood lipids, and fasting blood glucose （ FBG）, and to explore their protective effects on early renal damage of hypertension patients and on the metabolisms of blood lipids and blood glucose. Methods Totally 106 hypertension patients of YYDS were randomly assigned to two groups, 53 patients in the control group （treated by Iosartan potassium） and 53 patients in the treatment group （treated by JC ＋ Iosartan potassium）. The treatment lasted for 16 weeks. The serum changes of UA, Cys C, β2-MG, hs-CRP, blood lipids [ including total cholesterol（TC）, triglyceride （TG）, low density lipoprotein cholesterol （LDL-C）, and high density lipoprotein cho- lesterol （HDL-C） ], and FBG levels were measured to evaluate the renal protective effects and to assess their effect on the metabolisms of blood lipids and blood glucose. Results Compared with before treat- ment in the same group, the systolic blood pressure （SBP） decreased in the two groups after treatment, showing statistical difference （P 〈0.05, P 〈0.01 ）, but there was no statistical difference between the two groups （P 〉0.05）. The diastolic blood pressure （DBP） was not obviously declined in the two groups after treatment, showing no statistical difference. Compared with before treatment in the same group, the LDL-C level decreased obviously after treatment in the control group. But there was no obvious change in FBG, TC, HDL-C, and TG in the control group, showing no statistical difference when compared with be- fore treatment （P 〈0.05）. The FBG, TC, and LDL-C obviously decreased in the treatment group more ob- viously after treatment than before t

关 键 词：金水宝胶囊 胱抑素C Β2-微球蛋白 超敏C反应蛋白 尿酸 

分 类 号：R544.1[医药卫生—心血管疾病]